CurrentEndo
Get Weekly

CurrentEndo coverage · page 33 of 55

Diabetes, Obesity and Metabolism

Briefs 1,281–1,320 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Weight loss and body composition after compounded semaglutide treatment in a real world setting

    Cohort studyObesity

  2. Diabetes Obes Metab

    A preliminary randomized trial of a brief dissonance‐based type 2 diabetes prevention programme for adults with pre‐diabetes

    Randomized controlled trialT2D & other

  3. Diabetes Obes Metab

    Paediatric‐to‐adult transition in type 1 diabetes: A two‐centre experience of a structured program, 2014 to 2022

    Cohort studyT1D

  4. Diabetes Obes Metab

    Socioeconomic and mental health inequalities in global burden of type 2 diabetes: Evidence from the Global Burden of Disease Study 2021

    Cross-sectional studyT2D & other

  5. Diabetes Obes Metab

    Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis

    Secondary analysisT2D & other

  6. Diabetes Obes Metab

    Treatment outcomes with oral anti‐hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population‐based cohort study

    Cohort studyT2D & other

  7. Diabetes Obes Metab

    Association between the changes in the estimated glucose disposal rate and new‐onset cardiovascular disease in middle‐aged and elderly individuals: A nationwide prospective cohort study in China

    Cohort study

  8. Diabetes Obes Metab

    Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial

    Cohort studyT2D & other

  9. Diabetes Obes Metab

    Predictive models of post‐prandial glucose response in persons with prediabetes and early onset type 2 diabetes: A pilot study

    Research articleT2D & other

  10. Diabetes Obes Metab

    The predictive value of estimated glucose disposal rate and its association with myocardial infarction, heart failure, atrial fibrillation and ischemic stroke

    Cohort study

  11. Diabetes Obes Metab

    The cardio‐metabolic protein profile is associated with development of type 2 diabetes at long term follow‐up after gestational diabetes mellitus: Results from the OGFUS study

    Case-control studyDiabetes in pregnancy

  12. Diabetes Obes Metab

    Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease

    Cohort studyT2D & other

  13. Diabetes Obes Metab

    Exclusion of older persons from randomized controlled trials in type 2 diabetes: A cross‐sectional study

    Cross-sectional studyT2D & other

  14. Diabetes Obes Metab

    Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials

    Meta-analysisT2D & other

  15. Diabetes Obes Metab

    Heterogeneous blood pressure treatment effects on cognitive decline in type 2 diabetes: A machine learning analysis of a randomized clinical trial

    Secondary analysisT2D & other

  16. Diabetes Obes Metab

    Anti‐diabetic effects of GLP ‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review

    Meta-analysisObesity

  17. Diabetes Obes Metab

    Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study

    Cohort studyComplications

  18. Diabetes Obes Metab

    Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study)

    Randomized controlled trialT2D & other

  19. Diabetes Obes Metab

    Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study

    Research articleT2D & other

  20. Diabetes Obes Metab

    Evaluation of the efficacy and safety of controlled‐release phentermine/topiramate in adults with obesity in Korea: A randomized, double‐blind, placebo‐controlled, phase 4 trial ( QUEEN 's study)

    Randomized controlled trialObesity

  21. Diabetes Obes Metab

    Diagnostic accuracy of Agile‐4 score for liver cirrhosis in patients with metabolic dysfunction‐associated steatotic liver disease. A systematic review and meta‐analysis of diagnostic test accuracy studies

    Meta-analysisLipids & liver

  22. Diabetes Obes Metab

    Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial

    Randomized controlled trialT2D & other

  23. Diabetes Obes Metab

    Investigating the common genetic architecture and causality of metabolic disorders with neurodegenerative diseases

    Research article

  24. Diabetes Obes Metab

    Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China

    Cohort studyT2D & other

  25. Diabetes Obes Metab

    Impact of weight change on kidney transplantation outcomes: A systematic review and meta‐analysis

    Meta-analysis

  26. Diabetes Obes Metab

    Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis

    Meta-analysisT2D & other

  27. Diabetes Obes Metab

    Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study

    Secondary analysisT2D & other

  28. Diabetes Obes Metab

    Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes

    Cohort studyComplications

  29. Diabetes Obes Metab

    Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial

    Secondary analysisT2D & other

  30. Diabetes Obes Metab

    Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers

    Secondary analysisT2D & other

  31. Diabetes Obes Metab

    Identification of adipose tissue‐derived exosomal micro RNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies

    Diagnostic or prognostic studyT2D & other

  32. Diabetes Obes Metab

    Metformin lowers risk of hearing loss and mortality in type 2 diabetes

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control‐ IQ and MiniMed 780G according to patient characteristics

    Cohort study

  34. Diabetes Obes Metab

    Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study

    Cohort studyDiabetes in pregnancy

  35. Diabetes Obes Metab

    Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial

    Randomized controlled trialTechnology

  36. Diabetes Obes Metab

    Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial

    Secondary analysisComplications

  37. Diabetes Obes Metab

    SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis

    Meta-analysisT2D & other

  38. Diabetes Obes Metab

    Comparative efficacy and safety of dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes mellitus: A network meta‐analysis

    Meta-analysisT2D & other

  39. Diabetes Obes Metab

    Effectiveness and cost‐effectiveness of an app and rewards‐based intervention in type 2 diabetes: A randomised controlled trial

    Randomized controlled trialT2D & other

  40. Diabetes Obes Metab

    The fibrosis investigating navigator in diabetes ( FIND ): A tool to predict liver fibrosis risk in subjects with diabetes

    Diagnostic or prognostic studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,281–1,320 of 2,200, newest first